clinical trial · NCT04575025
Special Drug Use-results Surveillance of Tabrecta Tablets
Non-small Cell Lung CancerTabrecta tablets
brief summary
This study was an uncontrolled, primary data collection-based observational study to be conducted as a central registration system, multicenter special drug-use results surveillance. As an all-case study, this study collected all patients treated with Tabrecta in a specified post-marketing period. The observation period of each patient was up to 1 year (52 weeks)
started
Nov 2, 2020
primary completion
Oct 26, 2024
completion
Oct 26, 2024
last updated
Sep 15, 2025
official title
Special Drug Use-results Surveillance of Tabrecta Tablets (MET Exon 14 Skipping Mutation-positive Unresectable Advanced/Recurrent Non-small Cell Lung Cancer)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol